P1219 Late onset inflammatory bowel disease (IBD): Experience from two tertiary centers in Greece

Le résumé fourni par la source

Abstract Background The incidence of IBD in the elderly has increased in recent years1. Aim of the study was the reporting of disease and patient characteristics when IBD diagnosis was set after 60 years. Methods Data were retrieved retrospectively from patients’ medical records and included demographics, disease phenotype, types of treatment and mortality. Results Of 1017 registered patients, 133 were diagnosed ≥60 years (13.08%). 87 (65.4%) men, mean age at diagnosis 67.7 years (range 61-83). 74 with Crohn's disease (CD) (55.6%): 34 (45.9%) ileal disease (L1), 22 (29.7%) ileocolic (L3), 18 (24.3%) colonic disease (L2). 68 (91.9%) patients had inflammatory phenotype and 6 (8.1%) perianal disease. Of 59 patients with ulcerative colitis (UC), 30 (50.8%) had extensive disease (E3), 24 (40.7%) left sided colitis (E2) and 5 (8.5%) proctitis (E1). 57 (42.9%) patients were treated with mesalamine. 76 patients (57.1%) required biologic therapy: 25 (32.9%) anti-TNFs, 30 (39.5%) vedolizumab and 21(27.6%) ustekinumab. 27 (20.3%) patients underwent surgery for the disease. Co-morbidities: 74 patients (55.6%) suffered with arterial hypertension, 42 (31.5%) dyslipidemia, 33 (24.8%) diabetes mellitus and 19 (14.2%) coronary heart disease. Between the years 2014 - 2024 12 patients were deceased [8M/4F, median age 75.8 years (R65-85)]. 7 with ulcerative colitis (UC) and 5 with CD. The mortality rate in this population was 1.17%. The registered causes of death were: 5/12 (41.7%) malignancy, 4/12 (33.4%) cardiac events, 1/12 (8.3%) infection, 1/12 (8.3%) gastrointestinal cancer and 1/12 (8.3%) other causes. Conclusion 1) Less than 15% of patients were diagnosed with IBD after 60 years in a population from two tertiary centers 2) The majority required biologic therapy. 3) Mesalamine and vedolizumab were the most frequently administered drugs. 4) One fifth required surgery for their disease. 5) Co-morbidities were recorded in almost all cases. 6)Mortality rate was relatively low and the two leading causes of death were malignancies and cardiovascular events. References 1.Nimmons D, Limdi JK. Elderly patients and inflammatory bowel disease. World J Gastrointest Pharmacol Ther. 2016 Feb 6;7(1):51-65. doi: 10.4292/wjgpt.v7.i1.51. PMID: 26855812; PMCID: PMC4734955.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.